Nathaniel Hendrix1, David D Kim2,3, Krishna S Patel4, Beth Devine1,4,5. 1. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA. 2. Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. 3. Department of Medicine, Tufts University School of Medicine, Boston, MA, USA. 4. School of Pharmacy, University of Washington, Seattle, WA, USA. 5. Department of Health Services, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Health state utility values (HSUVs) are among the most influential attributes of cost-effectiveness analyses (CEAs). Our objective was to evaluate whether industry-funded studies select systematically different HSUVs as compared with studies without industry funding. METHODS: Among 10 diseases with high disease burden in the United States, we further identified 31 progressive health states. We then searched the Tufts Medical Center's CEA Registry to identify studies that included HSUVs and were submitted to the registry between 2002 and 2019. Two reviewers mapped the free-text descriptions of health states onto the 31 predefined health states. We analyzed the effect of industry funding on the point estimates of these HSUVs with a beta regression. We also analyzed the difference between related health states within studies by funding source with a linear regression. RESULTS: After identifying 26,222 HSUVs from 4198 CEAs, we matched 2573 HSUVs to the 31 predefined health states. We observed large variations within each health state: 12 of 31 health states included a range of HSUVs greater than 0.5. The point estimate model showed 1 statistically significant difference of 31 comparisons between studies with any industry funding and those without. The utility difference model found 3 significant differences out of 39 comparisons between CEAs with any industry funding and those without. LIMITATIONS: Inclusion of unpublished CEAs may have affected our conclusions about the effect of industry funding on selection of HSUVs. We also relied on free-text descriptions of health states available in the CEA Registry and did not include adjustment for multiple comparisons. CONCLUSION: Limited evidence exists that industry-funded studies select different HSUVs compared to non-industry-funded studies for the health states we considered.
BACKGROUND: Health state utility values (HSUVs) are among the most influential attributes of cost-effectiveness analyses (CEAs). Our objective was to evaluate whether industry-funded studies select systematically different HSUVs as compared with studies without industry funding. METHODS: Among 10 diseases with high disease burden in the United States, we further identified 31 progressive health states. We then searched the Tufts Medical Center's CEA Registry to identify studies that included HSUVs and were submitted to the registry between 2002 and 2019. Two reviewers mapped the free-text descriptions of health states onto the 31 predefined health states. We analyzed the effect of industry funding on the point estimates of these HSUVs with a beta regression. We also analyzed the difference between related health states within studies by funding source with a linear regression. RESULTS: After identifying 26,222 HSUVs from 4198 CEAs, we matched 2573 HSUVs to the 31 predefined health states. We observed large variations within each health state: 12 of 31 health states included a range of HSUVs greater than 0.5. The point estimate model showed 1 statistically significant difference of 31 comparisons between studies with any industry funding and those without. The utility difference model found 3 significant differences out of 39 comparisons between CEAs with any industry funding and those without. LIMITATIONS: Inclusion of unpublished CEAs may have affected our conclusions about the effect of industry funding on selection of HSUVs. We also relied on free-text descriptions of health states available in the CEA Registry and did not include adjustment for multiple comparisons. CONCLUSION: Limited evidence exists that industry-funded studies select different HSUVs compared to non-industry-funded studies for the health states we considered.
Entities:
Keywords:
cost-effectiveness analysis; publications; regression analysis; utility theory
Authors: C Bruce Baker; Michael T Johnsrud; M Lynn Crismon; Robert A Rosenheck; Scott W Woods Journal: Br J Psychiatry Date: 2003-12 Impact factor: 9.319
Authors: Christine M McDonough; Tor D Tosteson; Anna N A Tosteson; Alan M Jette; Margaret R Grove; James N Weinstein Journal: Med Decis Making Date: 2010-11-22 Impact factor: 2.583